Rétention de 7 biomédicaments et du tofacitinib chez des patients atteints de polyarthrite rhumatoïde n'ayant jamais reçu de biomédicaments ou ayant changé : l'étude de cohorte ANSWER
Arthritis Res Ther 2020;22:142
This paper is based upon a long-term cohort study, namely the ANSWER cohort, an observational multi-centre registry of RA patients in the Kansai district of Japan. Analyses demonstrate a difference in observed drug retention between bDMARDs-naïve and bDMARDs-switched patients. 7 bDMARD treatments were compared in patients with no prior exposure to biologics, with abatacept showing the greatest retention rate. In patients that had switched between these same bDMARDs or to tofacitinib throughout t...